relamorelin relamorelin relamorelin (inn, usan) (developmental code names rm-131, bim-28131, bim-28163) is a synthetic peptide, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (ghsr) which is under development by allergan pharmaceuticals for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa. it is a pentapeptide and an analogue of ghrelin with improved potency and pharmacokinetics. in humans, relamorelin produces increases in plasma growth hormone, prolactin, and cortisol levels, and, like other ghsr agonists, increases appetite. as of june 2015, relamorelin is in phase ii clinical trials for diabetic gastroparesis and constipation. the united states food and drug administration (fda) has granted fast track designation to relamorelin for diabetic gastroparesis. relamorelinclinical dataroutes ofadministrationsubcutaneousatc codenoneidentifiers iupac name 4-amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide cas number661472-41-9pubchem cid85364156chemspider32699203uniibiw199e18vkeggd10660 ychemical and physical dataformulac43h50n8o5smolar mass790.98 g·mol−13d model (jsmol)interactive image smiles c1ccc(cc1)c(c(=o)nc2(ccncc2)c(=o)n)nc(=o)(cc3cc4c3cccc4)nc(=o)(cc5csc6c5cccc6)nc(=o)c7ccncc7 inchi inchi=1s/c43h50n8o5s/c44-42(56)43(16-20-46-21-17-43)51-41(55)34(22-27-8-2-1-3-9-27)49-39(53)35(23-29-25-47-33-12-6-4-10-31(29)33)50-40(54)36(48-38(52)28-14-18-45-19-15-28)24-30-26-57-37-13-7-5-11-32(30)37/h1-13,25-26,28,34-36,45-47h,14-24h2,(h2,44,56)(h,48,52)(h,49,53)(h,50,54)(h,51,55)/t34-,35+,36+/m0/s1key:kubpnvypkpwgrj-livoikkvsa-n